SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

GRAIL Inc.

GRAIL is trending due to a significant drop in share price after its NHS-Galleri cancer screening trial missed its primary endpoint for statistically significant reduction in late-stage diagnoses. The community is sharply divided, with some investors arguing it's an overreaction given strong cash reserves and positive U.S. sales, while others question the test's efficacy and commercial viability amid high cash burn.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending following news of a royalty-based funding agreement, contingent on FDA approval for its lead prostate cancer candidate, alongside a proposed public stock offering. This dual financing is generating significant community discussion, with some investors concerned about potential dilution while others see it as a strategic move to secure capital for upcoming regulatory milestones and strengthen the company's commercialization position.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Canada, Mexico, Suriname, Argentina, Peru, Australia, Papua New Guinea, Ghana, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont Corp's shares are actively discussed following its earnings report, where impressive beats on revenue and EPS were overshadowed by a weaker 2026 outlook for gold production and higher costs. This mixed news has sparked debate among traders, with some viewing the pullback as an overreaction and a buying opportunity given high gold prices, while others express concern over the company's future guidance.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is trending sharply lower after reporting an unexpected loss and weak forecast, driven by rising credit loss provisions, fueling intense debate among investors about the long-term viability of its "buy now, pay later" business model. Many express skepticism about consumer debt repayment, while others view the significant price drop as an overreaction and a buying opportunity for a major player in the fintech sector.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending after its Q4 earnings report, which, despite a revenue beat, showed a net loss and increased operating expenses as the company aggressively invests in growth. The community is actively discussing whether the resulting share price dip is an overreaction to strategic long-term spending, especially given the strong revenue outlook and extended patent protection for its key products.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is trending as its investor conference highlighted substantial distribution gains from the Pepsi partnership and robust retail sales, driving strong community speculation about market dominance or a future acquisition; conversely, concerns persist regarding management's communication and potential stock manipulation.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending with high anticipation for its upcoming BLA resubmission for Deramiocel, a DMD treatment that showed robust Phase 3 efficacy, as the community discusses significant institutional interest, potential short squeeze dynamics, and hopes for accelerated FDA approval.

Deere & Co. engages in the manufacture and distribution of equipment used in agriculture, construction, forestry, and turf care. It operates through the following segments: Agriculture and Turf, Construction and Forestry, and Financial Services. The Agriculture and Turf segment focuses on the distribution and manufacture of a full line of agriculture and turf equipment and related service parts. The Construction and Forestry segment offers machines and service parts used in construction, earthmoving, road building, material handling and timber harvesting. The Financial Services segment finances sales and leases by John Deere dealers of new and used agriculture and turf equipment and construction and forestry equipment. The company was founded by John Deere in 1837 and is headquartered in Moline, IL.

Deere & Co.

Deere & Co

Deere & Co. is surging after delivering a strong earnings beat and raising its fiscal 2026 net income outlook, with management signaling a bottom to the agricultural cycle. The community is debating if this massive volume-driven rally is a sustainable breakout with higher price targets or an overbought "pump" detached from deeper valuation concerns.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Cape Canaveral, FL.

Starfighters Space Inc

Starfighters Space (FJET) is generating significant buzz as it prepares to ring the NYSE Opening Bell, with community discussions intensely focused on its low float and the potential for a massive short squeeze. This excitement is amplified by broader bullish sentiment surrounding the space sector and the anticipation of a major SpaceX IPO.

Sprouts Farmers Market, Inc. engages in the operation of healthy grocery stores. The firm specializes in fresh, natural and organic products. Its products include fresh produce, bulk foods, vitamins and supplements, grocery, meat and seafood, deli, bakery, dairy, frozen foods, body care and natural household items. The company was founded by Stan Boney, Shon Alexander Boney, and Kevin K. Easler on July 11, 2002 and is headquartered in Phoenix, AZ.

Sprouts Farmers Market Inc

Sprouts Farmers Market is trending after its Q3 earnings showed an EPS beat but a revenue miss and soft Q4 guidance, sparking a heated debate. Bulls are buying the dip, citing new store expansion and a $1 billion share repurchase program as long-term value, while bears fear continued downside due to perceived high prices and slowing comparable sales.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026...

Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program

Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program Atossa Therapeutics Maintains Strong...

Atossa Genetics (NASDAQ:ATOS) Sees Large Volume Increase - What's Next?

Atossa Genetics (NASDAQ:ATOS) Sees Large Volume Increase - Still a Buy...

<ul class="summary-bullets"><li>Each of 15 shares of the company’s common stock outstanding was combined into one new share of common stock.</li><li>No fractional shares were issued as a result of the split.&nbsp;</li><li>In January, the FDA granted Orphan Drug Designation to Atossa’s (Z)-endoxifen for the treatment of Duchenne muscular dystrophy.</li></ul>Shares of Atossa Therapeutics Inc. (ATOS) fell a steep 32% on Monday after the stock began trading on a split adjusted basis at trade open.Atossa <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001488039/000119312526021727/atos-20260120.htm">said</a> last week that its Board of Directors has approved a reverse stock split of the company’s common stock, at a ratio of 15:1, with an effective time of 12:01 a.m. Eastern Time on February 2, 2026.Each of 15 shares of the company’s common stock outstanding was combined into one new share that started trading on a split-adjusted basis on Monday. No fractional shares were issued as a result of the split.<h2 class="st-heading-2">New Designations</h2>In January, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to Atossa’s (Z)-endoxifen for the treatment of Duchenne muscular dystrophy. The drug was previously granted Rare Pediatric Disease designation for the treatment of DMD as well.Duchenne muscular dystrophy is a severe, progressive, X-linked genetic disorder, primarily affecting boys, characterized by the lack of the protein dystrophin, leading to muscle degeneration.The orphan drug designation is granted to therapies intended to treat rare diseases and offers incentives such as regulatory support. The drug is yet to be approved for any indication. However, the FDA gave clearances for studying the drug in metastatic breast cancer earlier in January.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ATOS stock stayed within the ‘bullish’ territory, while message volume remained at ‘high’ levels.A Stocktwits user highlighted concerns about a potential dilution. The company has cash and cash equivalents of $51.8 million as of September end. &nbsp;<stembedurl>https://www.stocktwits.com/St0ckt0k101/message/643702353</stembedurl>Another said that they are “relieved” the company didn’t get delisted.<stembedurl>https://www.stocktwits.com/RealTurd/message/643701100</stembedurl><a href="https://stocktwits.com/symbol/ATOS">ATOS stock</a> has lost 54% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-seemingly-confirms-xai-spacex-merger-talks/cZbgtmrR4kZ">Elon Musk Seemingly Confirms xAI-SpaceX Merger Talks</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Atossa Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ATOS Stock Tumbles 32% — Here’s What Retail Investors Think Of The Reverse Stock Split

Atossa Therapeutics said last week that its board has approved a reverse stock split of the company’s common stock, at a ratio of 15:1, with an effective time of 12:01 a.m. Eastern Time on February 2, 2026. 

Equity

Atossa Genetics Inc. (NASDAQ:ATOS) Short Interest Up 56.4% in January

Atossa Genetics Inc. (NASDAQ:ATOS - Get Free Report) was the recipient of a large increase in short interest in the month of January. As of January 15th, there was short interest totaling 3,621,023...

Atossa Genetics (NASDAQ:ATOS) Shares Set to Reverse Split on Monday, February 2nd

Atossa Genetics Inc. (NASDAQ:ATOS - Free Report) shares are going to reverse split on the morning of Monday, February 2nd. The 1-15 reverse split was announced on Monday, January 26th. The number of...

Atossa Genetics Inc. (NASDAQ:ATOS) Receives Consensus Recommendation of "Hold" from Analysts

Atossa Genetics Inc. (NASDAQ:ATOS - Get Free Report) has received a consensus rating of "Hold" from the five research firms that are covering the company, Marketbeat.com reports. Two analysts have...

Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025

Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025 Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The...

Atossa Secures FDA Orphan Drug Designation For (Z)-Endoxifen In Duchenne Muscular Dystrophy

(RTTNews) - Atossa Therapeutics, Inc. (ATOS) announced that the U.S. Food and Drug Administration's Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation to (Z)-endoxifen...

Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy

Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen...

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Current Price	$4.42
Prev Close	$4.34
Open	$4.35
Dividend Yield	0.00%
50-Day Moving Average	$8.89
Beta	1.27
Avg. Volume	140,846.69
PE Ratio	-1.23

52-Week High	$19.35
52-Week Low	$3.76
Market Capitalization	$37.37M
EPS (Annual)	-$3.04
Price to Book	0.75
Revenue Per Employee	$0.00

ATOS
Atossa Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ATOS News

ATOSAtossa Therapeutics Inc